Although oestrogen has profound skeletal effects in hens, the identity of its target cells in bone is still unclear. We wished to address this by indirect immunofluorescent detection of oestrogen receptors, using monoclonal antibodies, similar to our method for mammalian bone. Avian bone, however, is prone to autofluorescence at the excitation wavelength for fluorescein isothiocyanate, and non-specific binding of mammalian antibodies. We therefore improved receptor detection by comparing three commercially available monoclonal antibodies to the human oestrogen receptor. We found that the best identification of oestrogen target cells was produced by ID5 antibody diluted 1/20, with initial binding disclosed by Cy3trade mark-conjugated immunoglobin, which has similar fluorescence to rhodamine. Clear localisation of these cells was reliably obtained in sections of both receptor positive human breast tissue and hen oviduct. Preliminary observations showed that immunofluorescence in avian oviduct and undecalcified bone cryosections was stable after 6 weeks storage and of sufficient clarity for semiquantification. Thus, in hens aged 18 weeks (first ovarian follicle), osteoblasts and 38% of osteocytes were clearly immunofluorescent. After 8 to 10 weeks egg lay, receptor-positive osteocytes decreased in structural bone to 19%; cells adjacent to medullary bone and in marrow cavities were strongly immunofluorescent.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1080/03079459808419312 | DOI Listing |
Breast Cancer Res
January 2025
Austrian Breast & Colorectal Cancer Study Group (ABCSG), Vienna, Austria.
Background: The PALLAS trial investigated the addition of palbociclib to standard adjuvant endocrine therapy to reduce breast cancer recurrence. This pre-specified analysis was conducted to determine whether adjuvant palbociclib benefited patients diagnosed with lower risk stage IIA disease compared to those with higher stage disease.
Methods: PALLAS was an international, multicenter, randomized, open-label, phase III trial, representing a public-private partnership between Pfizer, the Austrian Breast Cancer Study Group, and the U.
J Cardiothorac Surg
January 2025
Kocaeli University Medical Faculty, Department of Thoracic Surgery, Kocaeli, Turkey.
Background: Lung cancer is the leading cause of cancer-related deaths worldwide. Therefore, the search for new biomarkers continues in order to diagnose lung cancer at an early stage. In this study, we investigated blood levels of G-protein associated membrane estrogen receptor (GPER)-1 and Raftlin as markers of early-stage in lung cancer.
View Article and Find Full Text PDFMol Med
January 2025
School of Public Health, Wenzhou Medical University, Wenzhou, 325035, China.
Hepatocellular carcinoma is one of the most common malignant tumors, and radiotherapy plays a pivotal role in its therapeutic regimen. However, radiotherapy resistance is the main cause of therapeutic failure in patients. Our previous study revealed that Adiponectin Receptor 1 (AdipoR1) is involved in regulating radiation resistance in liver cancer patients treated with stereotactic body radiotherapy.
View Article and Find Full Text PDFSci Rep
January 2025
The Second Department of Critical Care Medicine, The Second Affiliated Hospital of Anhui Medical University, Hefei, 230601, Anhui, China.
Although tamoxifen is commonly utilized as adjuvant therapy for Estrogen Receptor alpha (ERα)-positive breast cancer patients, approximately 30-50% of individuals treated with tamoxifen experience relapse. Therefore, it is essential to investigate additional factors besides ERα that influence the estrogen response. In this study, cross-analysis of databases were performed, and the results revealed a significant association between LINC00626 and ERα signaling as well as increased expression levels of this gene in tamoxifen-resistant cells.
View Article and Find Full Text PDFJ Steroid Biochem Mol Biol
January 2025
Laboratory of Experimental Endocrinology, Department of Pharmacology, Escola Paulista de Medicina (EPM), Universidade Federal de São Paulo (UNIFESP), São Paulo, SP, 04039-032, Brazil. Electronic address:
The aims of this study were to investigate the localization of non-phosphorylated β‑catenin and Galectin-3 (GAL-3), the regulation of the expression of both proteins by activation of estrogen receptors (ERs) and their role in tumorigenic characteristics of androgen-independent prostate cancer DU-145 cells. DU-145 cells were cultured in the absence (control), and presence of 17β-estradiol (E2). Cells were also untreated or pre-treated with the inhibitor of GAL‑3, VA03, or with a compound that disrupts the complex β-catenin-TCF/LEF transcription factor, PKF 118-310.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!